MX2024010233A - Moleculas de union especifica del vih. - Google Patents
Moleculas de union especifica del vih.Info
- Publication number
- MX2024010233A MX2024010233A MX2024010233A MX2024010233A MX2024010233A MX 2024010233 A MX2024010233 A MX 2024010233A MX 2024010233 A MX2024010233 A MX 2024010233A MX 2024010233 A MX2024010233 A MX 2024010233A MX 2024010233 A MX2024010233 A MX 2024010233A
- Authority
- MX
- Mexico
- Prior art keywords
- specific binding
- binding molecules
- hiv
- tcr
- tcrs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263312077P | 2022-02-20 | 2022-02-20 | |
| US17/938,321 US12103971B2 (en) | 2022-02-20 | 2022-10-05 | HIV specific binding molecules |
| PCT/EP2023/054236 WO2023156663A1 (en) | 2022-02-20 | 2023-02-20 | Hiv-specific binding molecules and tcr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010233A true MX2024010233A (es) | 2024-12-06 |
Family
ID=85321305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010233A MX2024010233A (es) | 2022-02-20 | 2024-08-20 | Moleculas de union especifica del vih. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250129161A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4479423A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025508738A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240149435A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023222190A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250782A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314832A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010233A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023156663A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202320012D0 (en) | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| GB202411647D0 (en) | 2024-08-07 | 2024-09-18 | Immunocore Ltd | Method |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998039482A1 (en) | 1997-03-07 | 1998-09-11 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
| CA2305630C (en) | 1997-10-02 | 2012-11-06 | Sunol Molecular Corporation | Soluble single-chain t-cell receptor proteins |
| DK1247095T3 (da) | 1999-12-06 | 2008-12-08 | Univ Illinois | TCR-proteiner med höj affinitet samt fremgangsmåder |
| WO2001062908A2 (en) | 2000-02-22 | 2001-08-30 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| PT1421115E (pt) | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
| NZ550815A (en) * | 2004-05-19 | 2009-04-30 | Immunocore Ltd | Method of improving T cell receptors |
| GB0506760D0 (en) * | 2005-04-01 | 2005-05-11 | Avidex Ltd | High affinity HIV TCRS |
| CN105461802A (zh) * | 2005-04-01 | 2016-04-06 | 英美偌科有限公司 | 高亲和力hiv t细胞受体 |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| GB201604953D0 (en) | 2016-03-23 | 2016-05-04 | Immunocore Ltd | T cell receptors |
| JP7599819B2 (ja) | 2016-06-02 | 2024-12-16 | イムノコア リミテッド | gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
-
2023
- 2023-02-20 JP JP2024548572A patent/JP2025508738A/ja active Pending
- 2023-02-20 CA CA3250782A patent/CA3250782A1/en active Pending
- 2023-02-20 WO PCT/EP2023/054236 patent/WO2023156663A1/en not_active Ceased
- 2023-02-20 IL IL314832A patent/IL314832A/en unknown
- 2023-02-20 KR KR1020247031311A patent/KR20240149435A/ko active Pending
- 2023-02-20 AU AU2023222190A patent/AU2023222190A1/en active Pending
- 2023-02-20 EP EP23706587.5A patent/EP4479423A1/en active Pending
-
2024
- 2024-06-27 US US18/757,296 patent/US20250129161A1/en active Pending
- 2024-08-20 MX MX2024010233A patent/MX2024010233A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314832A (en) | 2024-10-01 |
| WO2023156663A1 (en) | 2023-08-24 |
| CA3250782A1 (en) | 2023-08-24 |
| WO2023156663A9 (en) | 2024-01-18 |
| EP4479423A1 (en) | 2024-12-25 |
| AU2023222190A1 (en) | 2024-08-29 |
| US20250129161A1 (en) | 2025-04-24 |
| KR20240149435A (ko) | 2024-10-14 |
| JP2025508738A (ja) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miles et al. | CTL recognition of a bulged viral peptide involves biased TCR selection | |
| Chande et al. | S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3 | |
| Loffredo et al. | Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B* 08 and HLA-B* 2705, bind peptides with sequence similarity | |
| Goulder et al. | Evolution and transmission of stable CTL escape mutations in HIV infection | |
| Martin et al. | Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes | |
| Geyer et al. | Domain assembly, surface accessibility and sequence conservation in full length HIV‐1 Nef | |
| Dorrell et al. | Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa | |
| Vogel et al. | Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A* 02: a paradigm for virus evolution and persistence? | |
| Veenhuis et al. | Long-term remission despite clonal expansion of replication-competent HIV-1 isolates | |
| BR112018069275A2 (pt) | receptor de célula t, molécula de fusão anti-cd3 de receptor de célula t, ácido nucléico, vetor de expressão, célula, célula isolada ou que não ocorre naturalmente e composição farmacêutica | |
| Howard et al. | Genomic structure and nucleotide sequence analysis of a new HIV type 1 subtype A strain from Nigeria | |
| Brown et al. | Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors | |
| Costa et al. | Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1 | |
| Sunshine et al. | Fitness-balanced escape determines resolution of dynamic founder virus escape processes in HIV-1 infection | |
| Plaksin et al. | A three-domain T cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes | |
| Foster et al. | Genetic and functional diversity of human immunodeficiency virus type 1 subtype B Nef primary isolates | |
| EP4255572A1 (en) | T cell receptors and uses thereof | |
| Nappi et al. | Identification of a novel posttranscriptional regulatory element by using a rev-and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap | |
| Hounsell et al. | A proposed molecular model for the carboxy terminus of HIV-1 gp120 showing structural features consistent with the presence of a T-cell alloepitope | |
| Manrique et al. | Functional domains in the feline immunodeficiency virus nucleocapsid protein | |
| AU2002233424B2 (en) | Peptides having affinity for the GP120 viral protein and use thereof | |
| Simon et al. | A rat CD4 mutant containing the gp120-binding site mediates human immunodeficiency virus type 1 infection. | |
| Wu et al. | Mechanism of HIV-1 resistance to an electronically constrained α-helical peptide membrane fusion inhibitor | |
| Guilhaudis et al. | Solution structure of the HIV gp120 C5 domain | |
| IL314832A (en) | Hiv-specific binding molecules and tcr |